Sandra Huygen, business developer
After a PhD in life sciences at the University of Liege, Belgium, she graduated from the Solvay Brussels School, Belgium (University of Brussels, Belgium) where she got an MBA. Through her career both in biotech and pharmaceutical industries, Doctor Huygen specialized in offering integrated services from sciences to business by bridging the fundamentals of innovative sciences and the value chain of the health and market stakeholders' needs. Her understanding of the health stakeholders’ challenges, and ability to quickly respond with a holistic and comprehensive approach put her in a unique position to address RIMS customers’ needs.
Her key expertise in the health care and innovation sectors is listed as follows:
►Strategy: Corporate strategy, Alliances (clusters, partnerships), Business strategy, (Open) Innovation strategy, Business planning, Strategic management, Organizational structuring, Performance management, Sustainable development strategy.
► Assistance in public, private and philanthropic funding and fund raising at national and international levels.
► Program Management & Value creation: Assistance in management of complex programs (market opportunities, marketing, technology evaluation & transfer, R&D, product development, business development & opportunities, strategic planning, IP, accounting, QA-QS, HR and communication, project portfolio management, 360° valorisation of programs (spin-out, pitfalls, partnership opportunities, exploitation plans, identification of IP assets, invention disclosures, licensing opportunities, commercialisation opportunities...).
► Management of international multi-stakeholders programs & consortium (Academia, SME, large companies, Government, Clusters)
► Change & transition management
Over the past 10 years, Dr Huygen has held senior expert positions and collaborated with the following international companies and institutions: European commission, GSK Vaccines, Institut Pasteur, Pluriomics, Axenis, Quanteus, Iteos Therapeutics, Université de Liège/GIGA, Université Catholique de Louvain, Université de Namur, OMS, MDX Health, BioWin, Ovizio, Bioptis, Revatis, Aquilon Pharma, Targetome, Xibios, Sibelex, Pilotality, Matrix Clinical Research Management, Plus one, Aquilon, Symbiose Biomaterials.